Literature DB >> 27668060

Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia.

Loretta Fala.   

Abstract

Entities:  

Year:  2016        PMID： 27668060      PMCID： PMC5013843     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  5 in total

1.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

2.  Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.

Authors:  Frederick J Raal; Narimon Honarpour; Dirk J Blom; G Kees Hovingh; Feng Xu; Rob Scott; Scott M Wasserman; Evan A Stein
Journal:  Lancet       Date:  2014-10-01       Impact factor: 79.321

3.  PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.

Authors:  Frederick J Raal; Evan A Stein; Robert Dufour; Traci Turner; Fernando Civeira; Lesley Burgess; Gisle Langslet; Russell Scott; Anders G Olsson; David Sullivan; G Kees Hovingh; Bertrand Cariou; Ioanna Gouni-Berthold; Ransi Somaratne; Ian Bridges; Rob Scott; Scott M Wasserman; Daniel Gaudet
Journal:  Lancet       Date:  2014-10-01       Impact factor: 79.321

4.  Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

Authors:  Jennifer G Robinson; Bettina S Nedergaard; William J Rogers; Jonathan Fialkow; Joel M Neutel; David Ramstad; Ransi Somaratne; Jason C Legg; Patric Nelson; Rob Scott; Scott M Wasserman; Robert Weiss
Journal:  JAMA       Date:  2014-05-14       Impact factor: 56.272

5.  Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.

Authors:  Børge G Nordestgaard; M John Chapman; Steve E Humphries; Henry N Ginsberg; Luis Masana; Olivier S Descamps; Olov Wiklund; Robert A Hegele; Frederick J Raal; Joep C Defesche; Albert Wiegman; Raul D Santos; Gerald F Watts; Klaus G Parhofer; G Kees Hovingh; Petri T Kovanen; Catherine Boileau; Maurizio Averna; Jan Borén; Eric Bruckert; Alberico L Catapano; Jan Albert Kuivenhoven; Päivi Pajukanta; Kausik Ray; Anton F H Stalenhoef; Erik Stroes; Marja-Riitta Taskinen; Anne Tybjærg-Hansen
Journal:  Eur Heart J       Date:  2013-08-15       Impact factor: 29.983
  5 in total
  4 in total

Review 1.  Association of baseline LDL-C with total and cardiovascular mortality in patients using proprotein convertase subtilisin-kexin type 9 inhibitors: A systematic review and meta-analysis.

Authors:  Safi U Khan; Haris Riaz; Hammad Rahman; Muhammad U Khan; Muhammad Shahzeb Khan; Mohamad Alkhouli; Edo Kaluski; Thorsten M Leucker; Michael J Blaha
Journal:  J Clin Lipidol       Date:  2019-06-10       Impact factor: 4.766

2.  The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy.

Authors:  Yuichi Ikegami; Ikuo Inoue; Kaiji Inoue; Yuichi Shinoda; Shinichiro Iida; Seiichi Goto; Takanari Nakano; Akira Shimada; Mistuhiko Noda
Journal:  NPJ Aging Mech Dis       Date:  2018-06-22

Review 3.  PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis.

Authors:  Qianyun Guo; Xunxun Feng; Yujie Zhou
Journal:  Front Genet       Date:  2020-09-23       Impact factor: 4.599

4.  Maculopapular Exanthema After the Second Dose of Evolocumab.

Authors:  Victoria Ghernautan; Masoud Amini; Issac Sachmechi
Journal:  Cureus       Date:  2021-05-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.